Bill · S. 4472· Senate(119-S-4472)
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Introduced
- 4/30/2026
- Last activity
- 8/10/2026 — Held at the desk.
- Sponsored by
- Lisa Murkowski
- Cosponsors
- - 7 - 8
- Introduced
- Passed Senate
- Awaiting House
What this bill would do
This Act, known as the ``Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026'', aims to extend the provisions of the Accelerating Access to Critical Therapies for ALS Act. It reauthorizes specific provisions through fiscal year 2031. The bill includes updates to the grant application process for expanded access grants. It also modifies requirements for FDA action plans regarding rare neurodegenerative diseases. Additionally, the bill introduces new reporting requirements for the Secretary of Health and Human Services.
Yes
Does this make health care easier to get in general?+5
The bill extends the timeframe for expanded access grants and research related to ALS treatments through 2031.
Does this put more money into medical research?+5
The bill reauthorizes grants specifically for ALS research through fiscal year 2031.
Would people with disabilities be better off under this?+5
The bill supports the development of therapies for ALS, a debilitating neurodegenerative disease.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Extension of ALS Research Funding: The bill extends the timeframe for grants for ALS research through 2031, which supports the continued study of the disease (Section 2).
-
Improved Data Collection for Research: Grant applications must now include a description of how data generated through expanded access grants will be used to support research or development related to the prevention, diagnosis, mitigation, treatment, or cure of ALS (Section 3).
-
Enhanced Safety Monitoring: Entities receiving grants must now provide an assurance that they will promptly report available safety data from ongoing clinical trials to the Secretary (Section 3).
-
Better Oversight of Drug Efficacy: For grant renewals, there is a new requirement to request and assess enrollment, safety, and available efficacy data of the drug related to the treatment or cure of ALS (Section 3).
-
More Detailed FDA Action Plans: The bill updates requirements for FDA action plans to include descriptions of previous actions taken, planned actions, and any barriers to implementation, including resource estimates (Section 4).
Potential Negative Impacts for People
- No negative impacts are explicitly stated in the text provided.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Improves Healthcare Access+5Increases Research Funding+5
- Demographic And Interest Groups
- Good For People With Disabilities+5
- 8/10/2026
- Message on Senate action sent to the House.
- Held at the desk.
- Received in the House.
- 8/4/2026
- Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
- Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
- 7/23/2026
- 2 Cosponsors added.
- 7/21/2026
- 2 Cosponsors added.
- 7/16/2026
- Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
- 6/24/2026
- 2 Cosponsors added.
- 6/17/2026
- Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- 6/16/2026
- 4 Cosponsors added.
- 6/15/2026
- 4 Cosponsors added.
- 4/30/2026
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 1 Cosponsor added.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
John BarrassoRepublican · Wyoming
Jim BanksRepublican · Indiana
Susan CollinsRepublican · Maine
Shelley CapitoRepublican · West Virginia
Christopher CoonsDemocrat · Delaware
John CurtisRepublican · Utah
Steve DainesRepublican · Montana
Kirsten GillibrandDemocrat · New York
Maggie HassanDemocrat · New Hampshire
Amy KlobucharDemocrat · Minnesota
Edward MarkeyDemocrat · Massachusetts
Jeff MerkleyDemocrat · Oregon
David McCormickRepublican · Pennsylvania
Alex PadillaDemocrat · California
Sheldon WhitehouseDemocrat · Rhode Island